A new podcast from industry experts MarketScan explains why social determinants of health are critical to patient care.

The UK Government is pushing for a single, unified digital patient record within the NHS, but experts have shared cybersecurity concerns.

Dizal has received FDA approval for Zegfrovy to treat adults with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations.

By 2030, the cell and gene therapy market is projected to be worth £76.03bn, and logistics is essential in realising the ...

US President Donald Trump’s One Big Beautiful Bill Act (H.R. 1) has narrowly passed after US Vice President JD Vance broke a 50-50 deadlock in the US Senate.

Merck KGaA has concluded the previously announced acquisition of SpringWorks Therapeutics for an enterprise value of €3bn ($3.4bn).

Analysis shows Gilead’s recently approved drug for HIV prevention, Yeztugo, has the potential to transform the PrEP sector in the US.

Sanofi is to invest up to $25m in Adagene, which will enable the latter to fund its R&D efforts, including clinical development of muzastotug.

Uruguay’s MSP has tasked a working group and a proposal has been created by the Faculty of Chemistry at the University of Uruguay.

With its blockbuster Trikafta set to lose patent protection within the decade, Vertex is strengthening its cystic fibrosis portfolio.

The sale caps a difficult time for zilovertamab and ONCT-808 under Oncternal’s ownership. Zilovertamab was deprioritised by ...